Health Insurance Coverage for Persons in HIV Care, 20062012

Yehia, Baligh R. MD, MPP, MSHP*,†; Fleishman, John A. PhD; Agwu, Allison L. MD, ScM§; Metlay, Joshua P. MD, PhD; Berry, Stephen A. MD, PhD§; Gebo, Kelly A. MD, MPH§; for the HIV Research Network

JAIDS Journal of Acquired Immune Deficiency Syndromes:
doi: 10.1097/QAI.0000000000000251
Brief Report: Epidemiology and Prevention
Abstract

Abstract: We examined trends in health insurance coverage among 36,999 HIV-infected adults in care at 11 US HIV clinics between 2006 and 2012. Aggregate health insurance coverage was stable during this time. The proportions of patient-years with private, Medicaid, Medicare, and no insurance during this period were 15.9%, 35.7%, 20.1%, and 28.4%, respectively. Medicaid coverage was more prevalent among women than men, blacks, and Hispanics than whites, and individuals with injection drug use risk compared with other transmission risk factors. Hispanics and younger age groups were more likely to be uninsured than other racial/ethnic and older age groups, respectively.

Author Information

*Department of Medicine, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA;

Leonard Davis Institute of Health Economics, University of Pennsylvania, Philadelphia, PA;

Center for Financing, Access, and Cost Trends, Agency for Healthcare Research and Quality, Rockville, MD;

§Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD; and

Department of Medicine, Massachusetts General Hospital, Boston, MA.

Correspondence to: Baligh R. Yehia, MD, MPP, MSHP, Perelman School of Medicine, University of Pennsylvania, 1021 Blockley Hall, 423 Guardian Drive, Philadelphia, PA 19104 (e-mail: byehia@upenn.edu).

Supported by the Agency for Healthcare Research and Quality (HHSA290201100007C), the Health Resources and Services Administration (HHSH250201200008C), and the National Institutes of Health (K23-MH097647 to B.R.Y.).

Presented at the 2014 Conference on Retroviruses and Opportunistic Infections, March 3–6, 2014, Boston, MA.

BRY received grants to his institution from Gilead Sciences. KAG received grants to her institution from Tibotec, and provided consultancy to Tibotec and Bristol-Myers Squibb. The remaining authors have no conflicts of interest to disclose.

Supplemental digital content is available for this article. Direct URL citations appear in the printed text and are provided in the HTML and PDF versions of this article on the journal's Web site (www.jaids.com).

The views expressed in this article are those of the authors. No official endorsement by the Department of Health and Human Services, the National Institutes of Health, or the Agency for Healthcare Research and Quality is intended or should be inferred.

Received February 21, 2014

Accepted June 09, 2014

© 2014 by Lippincott Williams & Wilkins